SCYNEXIS, Inc., a biotechnology firm based in Jersey City, New Jersey, is spearheading the development of innovative products to combat fungal infections in the United States. The company's portfolio includes BREXAFEMME, a medication aimed at treating vulvovaginal candidiasis (VVC) and recurring VVC. Ibrexafungerp, the firm's lead drug candidate, is an intravenous medication that targets various fungal infections, such as invasive candidiasis, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. The company has research collaborations with notable players in the pharmaceutical industry, such as Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC, to develop and commercialize rights for ibrexafungerp. SCYNEXIS, Inc., previously known as SCYNEXIS Chemistry & Automation, Inc., changed its name to SCYNEXIS, Inc. in June 2002 since its incorporation in 1999.
SCYNEXIS's ticker is SCYX
The company's shares trade on the NASDAQ stock exchange
They are based in Jersey City, New Jersey
There are 11-50 employees working at SCYNEXIS
It is scynexis.com
SCYNEXIS is in the Healthcare sector
SCYNEXIS is in the Drug Manufacturers - Other industry
The following five companies are SCYNEXIS's industry peers: